What is HC Wainwright's Estimate for RARE FY2024 Earnings?

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) - Equities research analysts at HC Wainwright raised their FY2024 earnings per share estimates for Ultragenyx Pharmaceutical in a note issued to investors on Wednesday, November 6th. HC Wainwright analyst E. Arce now expects that the biopharmaceutical company will post earnings per share of ($6.26) for the year, up from their previous estimate of ($6.34). HC Wainwright has a "Buy" rating and a $95.00 price target on the stock. The consensus estimate for Ultragenyx Pharmaceutical's current full-year earnings is ($6.29) per share. HC Wainwright also issued estimates for Ultragenyx Pharmaceutical's Q4 2024 earnings at ($1.37) EPS, Q2 2025 earnings at ($1.11) EPS, Q3 2025 earnings at ($1.03) EPS, FY2025 earnings at ($4.29) EPS, FY2026 earnings at ($1.18) EPS, FY2027 earnings at $3.46 EPS and FY2028 earnings at $9.33 EPS.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last posted its quarterly earnings data on Tuesday, November 5th. The biopharmaceutical company reported ($1.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.45) by $0.05. The company had revenue of $139.49 million during the quarter, compared to analyst estimates of $135.28 million. Ultragenyx Pharmaceutical had a negative return on equity of 197.73% and a negative net margin of 106.93%. The firm's quarterly revenue was up 42.3% on a year-over-year basis. During the same quarter last year, the company earned ($2.23) earnings per share.

RARE has been the subject of several other research reports. The Goldman Sachs Group lifted their price objective on Ultragenyx Pharmaceutical from $67.00 to $76.00 and gave the company a "buy" rating in a research note on Friday, August 2nd. Wells Fargo & Company lifted their price target on Ultragenyx Pharmaceutical from $72.00 to $75.00 and gave the stock an "overweight" rating in a research note on Friday, August 2nd. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $116.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Wednesday. Canaccord Genuity Group lifted their price target on Ultragenyx Pharmaceutical from $109.00 to $121.00 and gave the stock a "buy" rating in a research note on Wednesday. Finally, Wedbush lifted their price target on Ultragenyx Pharmaceutical from $43.00 to $46.00 and gave the stock a "neutral" rating in a research note on Friday, August 2nd. Two investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $86.69.

Ultragenyx Pharmaceutical Price Performance

NASDAQ:RARE traded down $0.07 during trading hours on Friday, hitting $50.36. 1,246,767 shares of the company's stock traded hands, compared to its average volume of 783,398. Ultragenyx Pharmaceutical has a 52 week low of $34.06 and a 52 week high of $60.37. The business's fifty day simple moving average is $55.19 and its two-hundred day simple moving average is $48.12.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Headlands Technologies LLC bought a new position in Ultragenyx Pharmaceutical during the 1st quarter valued at approximately $28,000. nVerses Capital LLC bought a new position in shares of Ultragenyx Pharmaceutical in the 2nd quarter worth approximately $33,000. UMB Bank n.a. raised its position in shares of Ultragenyx Pharmaceutical by 58.1% in the 2nd quarter. UMB Bank n.a. now owns 958 shares of the biopharmaceutical company's stock worth $39,000 after acquiring an additional 352 shares in the last quarter. Values First Advisors Inc. bought a new position in shares of Ultragenyx Pharmaceutical in the 3rd quarter worth approximately $56,000. Finally, Capital Performance Advisors LLP bought a new position in shares of Ultragenyx Pharmaceutical in the 3rd quarter worth approximately $107,000. Institutional investors own 97.67% of the company's stock.

Insider Activity

In other news, CFO Howard Horn sold 7,465 shares of the business's stock in a transaction dated Thursday, October 10th. The stock was sold at an average price of $52.76, for a total value of $393,853.40. Following the completion of the sale, the chief financial officer now owns 92,301 shares of the company's stock, valued at approximately $4,869,800.76. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other Ultragenyx Pharmaceutical news, CEO Emil D. Kakkis sold 20,000 shares of the company's stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $55.85, for a total transaction of $1,117,000.00. Following the completion of the transaction, the chief executive officer now owns 2,223,985 shares of the company's stock, valued at $124,209,562.25. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Howard Horn sold 7,465 shares of the company's stock in a transaction that occurred on Thursday, October 10th. The shares were sold at an average price of $52.76, for a total value of $393,853.40. Following the transaction, the chief financial officer now directly owns 92,301 shares of the company's stock, valued at $4,869,800.76. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 27,556 shares of company stock valued at $1,515,967. Insiders own 5.80% of the company's stock.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.